Abstract

ObjectiveThe objective of this study is to evaluate the efficacy of adjuvant interferon therapy for hepatitis B virus-related hepatocellular carcinoma (HCC) after different previous therapy.MethodsAn electronic search for articles about adjuvant treatment with IFN for patients with HCC published between 2000 and 2015 was conducted in MEDLINE, PubMed, Cochrane Library, and EMBASE databases. All data was tested with Stata12.0 software.ResultsSix trials with a total of 1054 subjects were screened according to inclusion and exclusion standards. Five hundred and seventeen HCC patients were treated with adjuvant treatment with IFN and 537 patients with placebo. Compared to the control group, both the recurrence rate and death rate of HCC in IFN group were statistically lower, especially after transhepatic arterial chemotherapy and embolization (TACE) treatment and both TACE and resection according to subgroup analysis.There is no statistical significance on the both recurrence and death rate of HBV-related hepatocellular carcinoma after surgical resection treatment (RR = 0.96, 95 % CI, 0.84 to 1.1, p = 0.59 for recurrence and RR = 0.78, 95 % CI, 0.60 to 1.04, p = 0.09 for death rates).ConclusionsAdjuvant IFN therapy may significantly reduced mortality as well as recurrence rate of patients with HBV-related HCC after no matter what the previous treatment. On the other hand, there is no statistical significance on the recurrence rate and mortality after surgical resection only. More research is needed into the relationship between effect of adjuvant interferon therapy and previous therapy, especially TACE.

Highlights

  • Primary liver cancer is mainly composed of hepatocellular carcinoma (HCC), which is the world’s third most common cause of cancer deaths [1]

  • About 55 % liver cancer deaths worldwide occur in China, because of the highest age-adjusted incidence of HCC due to chronic hepatitis B (CHB) [2]

  • The clinical data is put forward by evidence-based medicine system evaluation, and a meta-analysis using fixed/random effects model is used to study the influence of recurrence rate and mortality of viral hepatitis liver cancer, which is treated by interferon after surgical resection or transhepatic arterial chemotherapy and embolization (TACE) or both surgical resection and TACE, and provide the foundation for evidence-based medicine

Read more

Summary

Introduction

Primary liver cancer is mainly composed of hepatocellular carcinoma (HCC), which is the world’s third most common cause of cancer deaths [1]. About 55 % liver cancer deaths worldwide occur in China, because of the highest age-adjusted incidence of HCC due to chronic hepatitis B (CHB) [2]. Most patients received surgical resection or transhepatic arterial chemotherapy and embolization (TACE) [4]. The recurrence rate after 3 years of liver cancer which is treated by pure resection or chemotherapy via hepatic artery embolism is more than 50 %, which is. The clinical data is put forward by evidence-based medicine system evaluation, and a meta-analysis using fixed/random effects model is used to study the influence of recurrence rate and mortality of viral hepatitis liver cancer, which is treated by interferon after surgical resection or TACE or both surgical resection and TACE, and provide the foundation for evidence-based medicine.

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.